

## PEI Pharmacare Bulletin

Issue (2021 - 1)

January 11, 2021

### NEW PRODUCT(S) ADDED TO THE PEI PHARMACARE FORMULARY (EFFECTIVE DATE: JANUARY 25, 2021)

Product (Generic name)	Product (Brand name)	Strength	Dosage Form	DIN	MFR
Cinacalcet	Various Generics	30 mg 60 mg 90 mg	Tablet Tablet Tablet	Various	Various
Criteria	Dialysis patient with severe hyperparathyroidism (PTH > 88 pmol/L measured twice in 3 months at least 6 weeks apart) who have maximized phosphate binder therapy and vitamin D therapy. Patients must have one of the following: <ul style="list-style-type: none"><li>corrected serum calcium &gt; 2.54 mmol/L; serum phosphate &gt; 1.8 mmol/L; <b>or</b></li><li>presence of symptoms related to hyperparathyroidism (i.e. bone pain).</li></ul>				
Program Eligibility	Family Health Benefit Drug Program, Financial Assistance Program, Generic Drug Program, Seniors Drug Program, Nursing Home Program, Catastrophic Drug Program				